Pyridone Derivative Agonists for Cognitive Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive impairments associated with conditions like Alzheimer's disease and ADHD lack effective agonists or partial agonists for the α7 nicotinic acetylcholine receptor, which are crucial for improving cognitive functions and attention.
Innovation Solution
Development of azabicycloalkane-substituted pyridone derivative compounds that act as agonists or partial agonists for the α7 nicotinic acetylcholine receptor, specifically represented by Formulae I and II, or their pharmaceutically acceptable salts, isomers, solvates, or hydrates, which can be used to enhance cognitive functions and treat related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cognitive impairments are used, then existing therapeutic options are available, but effective agonists or partial agonists for the α7 nicotinic acetylcholine receptor are lacking
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of pyridone derivatives, specifically varying substituents at different positions (R1, R2, R3, R4, R5, R6) to optimize binding affinity and agonist activity at the α7 nicotinic acetylcholine receptor. This includes changing aromatic groups, heteroaryl groups, alkyl groups, and other substituents to achieve desired pharmacological effects.
Solution Approach 2:
The patent segments the molecular structure into distinct functional regions with specific substituents that can be independently optimized. The core pyridone structure is divided into multiple positions where different pharmacophoric elements can be attached, allowing separate optimization of binding affinity, selectivity, and pharmacological activity.
2Reliability
If azabicycloalkane-substituted pyridone derivative compounds are developed as agonists, then cognitive functions and attention can be improved, but the complexity of drug development increases
Solution Approach 1:
The patent creates a universal scaffold (pyridone derivative) that can serve multiple therapeutic purposes for different cognitive disorders including Alzheimer's disease, ADHD, and other neurocognitive impairments. The core structure with variable substituents provides a multi-functional platform that addresses various cognitive functions through α7 receptor modulation.
Data Source
AI summary
A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.